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ABSTRACT  
BACKGROUND: 
Glucocorticoids have never been studied in a placebo-controlled manner in 
giant cell arteritis (GCA) but their effectiveness  is well established.  However 
evidence for efficacy for the use of immusuppresant drug as steroid-sparing in 
this disease is highly desirable, especially in elderly patients.  
OBJECTIVES:  
We report the use of mycophenolate mofetil (MMF) as steroid sparing agent in 
three patients (mean age 78 years) with GCA at high risk for long-term high 
dose glucocorticoids because of type II mellitus diabetes, obesity, 
hypertension and osteoporosis.  
DESIGN and SETTINGS: 
Clinical monitoring and assessment of laboratory parameters were done 
weekly (first month) and then patients were seen in the clinic every 2 weeks. 
Vascular lesions also were monitored at the onset and during the follow-up by 
using Doppler ultrasonography (every 3 months).  
RESULTS:  
All the three patients showed clinical benefit, and they were also able to taper 
steroid use in a more rapid regimen compared to the recently suggested 
steroid reduction approach. MMF was well tolerated, and no signs of toxicity 
were observed in a mean 21.6 months (12-29) of follow-up. 
CONCLUSION:  
Mycophenolate mofetil may be considered a steroids-sparing agent in elderly 
patients with GCA but before results of controlled trials become available, it 
may be considered only for patients who do not improve or stabilize with 
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conventional therapy or in subjects in whom a reduction of steroid dose is 
largely auspicable.  
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INTRODUCTION  
 
Giant cell arteritis (GCA), also known as temporal arteritis, is a vasculitis of 
medium and large vessels (1). Many of the most concerning features of the 
disease result from vascular inflammation involving cranial branches of the 
arteries that originate from the aortic arch (2,3). Glucocorticoids have never 
been studied in a placebo-controlled manner in GCA but their effectiveness is 
well established. Glucocorticoids may predispose to, or worsen preexisting 
conditions, as osteoporosis or mellitus diabetes Type II (DM). This is a 
particular concern because the disease affects postmenopausal women and 
aged men. However evidence for efficacy for the use of immunosuppresant 
drugs as steroid-sparing in this disease is lacking. The results of RCTs of 
Methotrexate (MTX) in GCA have led to somewhat divergent conclusions 
(4,5,6). Thus, additional work toward the identification of effective prednisone-
sparing agents is highly desirable.  
We report our experience in the treatment with MMF as a steroid-sparing 
agent of three elderly subjects with new-onset GCA at high-risk for the use of 
long-term high dose glucocorticoids because of DM, obesity, hypertension 
and osteoporosis.  
MMF was reported as a safe and tolerated treatment in other autoimmune 
disorders affecting older population. (7) 
The diagnosis of new-onset GCA was made according to American College of 
Rheumatology criteria (8) and all the patients underwent to a biopsy of the 
temporal artery. (Fig.1). All the patients gave written informed consent. 
Oral MMF (2 g/d) was given to three patients in two divided doses.  
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Patients were evaluated at baseline and after treatment according to the 
following criteria: 1) presence of headache, abrupt onset of visual 
disturbances or Jaw claudication ; 2) systemic symptoms including fever not 
attributable to infection, polyarthralgias, and polymyalgias; and 3) elevated 
Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP).  
Clinical evaluation and assessment of laboratory parameters were done 
weekly during the first month of treatment. Thereafter, patients were seen in 
the clinic every 2  weeks.  
Vascular lesions were also qualitatively assessed by using Doppler 
UltraSonography (DUS) of the temporal artery every 3 months during the 
follow-up (12-29 months). 
 
Clinical Characteristics at Baseline 
Baseline clinical characteristics are shown in Tab.1. All the patients had a 
clinical history of DM in oral therapy (metformin) and hypertension needing at 
least three anti-hypertensive drugs (ramipril, amlodipine, and 
hydrochlorothiazide); two patients were obese (patient 2 and 3, Body Mass 
Index 32 and 41 respectively); one of them suffered from osteoporosis (T 
score -2.9 at Dual energy X-ray Absorptiometry) and she was given 
alendronate sodium (70mg/weekly).  
Clinical Outcome 
Patient responses to MMF therapy are summarized in Tab.1. 
No signs of clinical relapse was detected over a mean of 21.6 months (12-29) 
of follow-up. 
Patient 1 
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The patient’s systemic symptoms resolved 2 weeks after initiation of therapy, 
and his ESR rapidly decreased (Fig.1).  Starting prednisone therapy was 50 
mg/day associated to MMF, both administered immediately after the 
histological confirmation of the diagnosis.  After 1 month of MMF therapy, the 
prednisone dose could be tapered to the dose of 15 mg/day. Prednisone 
could be tapered to 7.5 mg/d after three months. After 12 months of follow-up, 
the patient remains in stable clinical condition with no instrumental evidence 
of disease progression. Headache or jaw claudication attacks never recurred. 
DUS performed after 9 months from the CGA diagnosis,  showed the 
resolution of the previously described vascular lesions. DM and hypertension 
were under control and no therapy adjustment was needed. At the last 
observation (10 months after diagnosis) the patient was given 5 mg/d 
prednisone and 2 g/day MMF. 
Patient 2  
2 weeks after initiation of therapy (starting dose 50 mg/day of prednisone 
associated to MMF), systemic symptoms and headaches resolved. Laboratory 
markers of inflammation were shown in Fig.1 . The steroid dose was halved 
from the initial dose after 3 weeks of therapy with MMF. An ultrasonogram 
obtained by DUS showed no deterioration of the previously described 
vascular lesions during the 24 months of follow-up. The prednisone was 
tapered to a daily dose of 10 mg within 4 months. The patient felt so well and 
no change in diabetic or anti-hypertensive therapy was needed. At the last 
observation (24 months after diagnosis) the patient was given 7.5 mg/d 
prednisone and 2 g/d MMF. 
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Patient 3 
Systemic symptoms resolved 3 weeks after initiation of therapy (starting dose 
25 mg/day of prednisone associated to MMF).  Laboratory markers of 
inflammation were shown in Fig.1 Fever disappeared and never relapsed 
during the follow-up. After 1 month of MMF therapy given after the histological 
confirmation of the diagnosis, the prednisone dose could be tapered at the 
dose of 12.5 mg in 1 month, and after a 29 months of follow-up a dose of 
prednisone of 5 mg was reached. Headache never recurred. DUS performed 
after 9 months from the diagnosis, showed the resolution of the previously 
described vascular lesions. DM and hypertension were under control and no 
therapy adjustment was needed. At the last observation (27 months after 
diagnosis) the patient was given 5 mg/d prednisone and 2 g/d MMF. 
Side Effects 
All patients tolerated MMF without any major toxicity.  
 
DISCUSSION 
Therapeutic decisions in GCA are often guided by individual patient variables 
including location and severity of arterial lesions, availability of collateral 
circulation, nature and intensity of symptoms, and the risks of drug toxicity. 
The present report showed that MMF therapy was well tolerated, could control 
GCA activity disease, and also allow to taper prednisone dose in a more rapid 
regimen compared to the recently suggested steroid reduction approach 
(Fig.1) (9).  
After 1 month of MMF, the prednisone dose could be tapered at the mean 
dose of 17.5 mg (12.5-25 mg), with a first month-mean reduction of more than 
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a half of initial dose. Instead, referring to the recent guidelines (9), no steroid 
reduction is suggested in the 3-4 weeks of glucocorticoids treatment; 
moreover a comparable reduction of more than a half of the initial dose was 
reached only after at least 7 weeks from the starting of the therapy (Fig.1). 
MMF allowed a significant decrease in the level of ESR and CRP values. 
Glucocorticoidss constitute the first-line treatment for active arterial 
inflammation and an initial daily dose of 40-60 mg of prednisone or its 
equivalent in single or divided doses is adequate in almost all cases of GCA 
(10). Some patients respond to doses as low as 20 mg/day, but this dose is 
seldom used, primarily because of concern for the potential consequences of 
undertreatment (11). Although remission is achieved in nearly all cases, 
(12,13), relapses during glucocorticoids tapering may occur. Moreover, the 
use of glucocorticoids may also predispose to, or worsen preexisting 
conditions, as osteoporosis, DM, hypertension and obesity such in cases we 
proposed. This is a particular concern because these diseases mainly affect 
postmenopausal women and older men. Therefore, other immunosuppressive 
drugs may be potentially added to glucocorticoids with the aim of curbing 
disease progression and reducing disease and glucocorticoids-related 
morbidity.  
MTX is an immunosuppressant proposed for GCA treatment. The results of  
RCTs of MTX in GCA have led to somewhat divergent conclusions (4-6) and  
taken together, the results of these trials are difficult to reconcile entirely and 
they have recently been the subject of a formal meta-analysis (14). According 
to this analysis, adjunctive methotrexate treatment for GCA reduced the risk 
of both a first and a second relapse (hazard ratios 0.65 and 0.49, 
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respectively). By contrast, MTX would not appear to act quickly, and cannot 
thus be recommended as a replacement for glucocorticoids at disease onset. 
In such a contest, additional work toward the identification of effective 
prednisone-sparing agents is largely desirable. (15)  
MMF has been used most often in transplant recipients and the rationale for 
using MMF in patients with GCA is supported by the drug’s 
immunosuppressive properties and its unique action in preventing 
lymphocyte-mediated vascular damage; moreover, several evidences about 
the use of MMF in large vassel vasculitis (e.g. Takayasu arteritis) are reported 
in literature (16). Its good safety profile may also prove valuable for steroid-
sparing potential effect. 
We based our definition of disease activity on clinical and serologic 
parameters. Ultrasonographic evaluation was also performed. However,  the 
evaluation of the clinical response in GCA is difficult to assess because no 
accurate definition of disease activity and remission is available; although 
subjective symptoms, laboratory data, and angiographic changes have been 
proposed to evaluate disease status, none of them are specific. 
Therefore, this is a preliminary report of three patients in whom we believed 
the use of GC at the conventional dose was not recommended for the high 
metabolic risk due to co-existent DM, hypertension, osteoporosis and obesity. 
Moreover, although  the clinical setting recommended a rapid therapeutic 
decision, in our opinion the absence of catastrophic events (such as visual 
disturbances/visual loss) permitted us to avoid the use of high dose of 
glucocorticoids, potentially linked with complications in such patients; the use 
of a steroid-sparing agent was so widely recommended.  
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All three patients reported a subjective benefit. During the observation period, 
none experienced new-onset of headache or jaw claudication; clinical 
examination showed no evidence of tenderness of temporal arteritis. None of 
them had fever, and all systemic symptoms resolved. In all patients, tapering 
of steroid therapy was achieved. Three patients completely resumed lifestyles 
they had long abandoned because of their illness. Diabetes and hypertension 
was under control during the follow-up. Anyway, GCA is a remitting and 
relapsing disease; therefore, we cannot exclude the possibility that our 
patients’ positive response may be due to spontaneous remission rather than 
the effect of the drug. However, the concomitant subjective benefit and 
normalization of laboratory data should be consistent with the hypothesis that 
the clinical improvement was due to therapy with MMF associated to 
glucocorticoids. A longer follow-up period is needed to assess duration of 
remission. 
In our experience, MMF proved to be safe and well tolerated. None of the 
patients had leucopenia, thrombocytopenia, elevated liver enzyme levels, or 
gastrointestinal discomfort; therefore, the dosage of 2 g/d could be 
maintained.  
However, the follow-up may have been too short for more serious adverse 
effects to have developed.  
CONCLUSION 
MMF may be considered a steroids-sparing agent in patients with GCA. 
Before results of controlled trials become available, MMF should be 
considered only for patients who do not improve or stabilize with conventional 
therapy or in subjects in whom a reduction of steroid dose is largely 
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auspicable for co-existing conditions such as DM, osteoporosis, hypertension 
and obesity.    
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Figures 
Figure 1  - Serologic and histopathology assessment, and therapy regimen of 
the patients. 
1.a Inflammation scores, Erythrocyte Sedimentation Rate (ESR) and C-
Reactive Protein (CRP), of the three patients during the follow up. 
1.b. Steroid tapering regimen: the chart shows mean prednisone dose in our 
experience in comparison to the dosage recently suggested. MMF allowed a 
more rapid prednisone tapering (p<0.001, with paired two-sample t-tests) 
compared to conventional steroid dosage suggested by Dasgupta et co-
workers. (Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, 
Bourke B, et al. BSR and BHPR Standards, Guidelines and Audit Working 
Group. BSR and BHPR guidelines for the management of giant cell arteritis. 
Rheumatology (Oxford) 2010;49: 1594-7.) 
1.c. Histopathology findings in temporal artery: chronic inflammatory infiltrates 
consisting of monocytes, lymphocytes were present associated with sporadic 
giant cells (arrow) and fragmentation of internal elastic lamina. 
 
Tables 
Table 1  - Characteristics of 3 Patients with GCA at onset of disease and 
while treatment with MMF at the end of follow-up. 
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Figure 1. 
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Tab.1. Characteristics of 3 Patients with GCA at onset of disease and while treatment with MMF at the end of 
follow-up. 
Onset 
Patient 
 
Age 
(years) 
Sex Onset of 
Disease 
(biopsy) 
Disease Characteristic Inflammation score at onset Doppler 
ultrasonography 
Risk factor for 
long term high 
dose use 
 of steroids 
Headache Jaw 
claudication 
Sistemic symptoms ESR, 
mm/h  
CRP (mg/dl) 
(normal value 
<0.5 mg/dl) 
1 75 M 14/12/09 Yes 
  
Yes Yes (fever not 
attributable to 
infection; 
polyarthralgias) 
78 7.3 hypoechogenic 
halo sign 
DM, 
hypertension 
2 69 F 15/11/08 Yes Yes Yes (fever not 
attributable to 
infection, 
polyarthralgias  
polymyalgias) 
60 2.7 features as 
stenosis or 
occlusion 
DM, obesity, 
hypertension,os
teoporosis 
3 90 M 13/06/08 Yes No Yes (asthenia, fever 
not attributable to 
infection, 
polyarthralgias) 
76  8.0 hypoechogenic 
halo sign 
DM, obesity, 
hypertension 
While treatment with MMF at the end of follow-up 
Patient 
 
Month of 
follow up  
Prednisone  
Starting 
Dosage/ Final 
Dosage (mg/d) 
Disease Characteristic  Inflammation score Response to therapy 
headache Jaw 
claudication 
Systemic symptoms  
 
ESR 
(mm/h) 
CRP 
(mg/dl) 
(normal value 
<0.5 mg/dl) 
1 10 50/ 5 No No No 6  <0.5 Yes 
2 22 50/  7.5 No No No 24  0.7 Yes 
3 27 25/ 5 No No No 6  <0.5 Yes 
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